What is the current stock price of NervGen Pharma Corp. (NGENF)?

As of the latest market data, NervGen Pharma Corp. (NGENF) is trading at $3.95. The stock has seen a loss of -2.47% today.

Does NervGen Pharma Corp. (NGENF) pay a dividend?

Based on current data, NervGen Pharma Corp. does not have a confirmed active dividend policy.

What is the market cap of NervGen Pharma Corp.?

The current market capitalization of NervGen Pharma Corp. (NGENF) is approximately unavailable.

NGENF

NervGen Pharma Corp.·Healthcare

3.95

2.469%(−0.10)

Close Price

5.74

45.316%(+1.79)

Pre-Market

Last Updated: — ET

52W L: $1.5052W H: $6.30

Company Profile

NervGen Pharma Corp., together with its subsidiaries, engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage. Its lead product candidate is NVG-291 that is in phase 1 clinical trial for the treatment of spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. The company has a licensing agreement with Case Western Reserve University to research, develop, and commercialize a patented technology with therapeutic potential for SCI and other conditions associated with nerve damage. NervGen Pharma Corp. was incorporated in 2017 and is based in Vancouver, Canada.

Sector

Healthcare

Industry

Biotechnology

Employees

IPO Date

2019-04-03

Beta

0.76

Websitewww.nervgen.com↗